Literature DB >> 11097125

Bosentan and the endothelin system in congestive heart failure.

S H Ellahham1, V Charlon, Z Abassi, K A Calis, W K Choucair.   

Abstract

The endothelin system appears to play an important role in the pathophysiology of congestive heart failure (CHF). Endothelin receptor antagonists represent a novel class of agents that are being evaluated for their potential benefits in treating various cardiovascular disorders. Bosentan is an orally active endothelin receptor antagonist that has been studied for the treatment of CHF. Early clinical experience with bosentan has confirmed some benefits on hemodynamic parameters in patients with CHF. Its role in slowing the progression of the disease and improving survival remains to be elucidated.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11097125      PMCID： PMC6655168          DOI： 10.1002/clc.4960231128

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN： 0160-9289            Impact factor:   2.882


  58 in total

1.  The pharmacology of bosentan.

Authors:  V Breu; S I Ertel; S Roux; M Clozel
Journal:  Expert Opin Investig Drugs       Date:  1998-07       Impact factor: 6.206

2.  Contractile activity of three endothelins (ET-1, ET-2 and ET-3) on the human isolated bronchus.

Authors:  C Advenier; B Sarria; E Naline; L Puybasset; V Lagente
Journal:  Br J Pharmacol       Date:  1990-05       Impact factor: 8.739

3.  Endothelin immunoreactivity of airway epithelium in asthmatic patients.

Authors:  D R Springall; P H Howarth; H Counihan; R Djukanovic; S T Holgate; J M Polak
Journal:  Lancet       Date:  1991-03-23       Impact factor: 79.321

4.  Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor.

Authors:  W Kiowski; T F Lüscher; L Linder; F R Bühler
Journal:  Circulation       Date:  1991-02       Impact factor: 29.690

5.  Messenger RNA expression and synthesis of endothelin-1 along rat nephron segments.

Authors:  K Ujiie; Y Terada; H Nonoguchi; M Shinohara; K Tomita; F Marumo
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

6.  Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis.

Authors:  A Lerman; B S Edwards; J W Hallett; D M Heublein; S M Sandberg; J C Burnett
Journal:  N Engl J Med       Date:  1991-10-03       Impact factor: 91.245

7.  Plasma endothelin in chronic heart failure.

Authors:  J J McMurray; S G Ray; I Abdullah; H J Dargie; J J Morton
Journal:  Circulation       Date:  1992-04       Impact factor: 29.690

8.  Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction.

Authors:  M J Sumner; T R Cannon; J W Mundin; D G White; I S Watts
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

9.  Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells.

Authors:  K Janakidevi; M A Fisher; P J Del Vecchio; C Tiruppathi; J Figge; A B Malik
Journal:  Am J Physiol       Date:  1992-12

10.  Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure.

Authors:  R J Cody; G J Haas; P F Binkley; Q Capers; R Kelley
Journal:  Circulation       Date:  1992-02       Impact factor: 29.690
View more
  2 in total

1.  Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole.

Authors:  Paul L M van Giersbergen; Atef Halabi; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2002-06       Impact factor: 4.335

2.  Cardioprotective Effects of Mebudipine in a Rat Model of Doxorubicin-Induced Heart Failure.

Authors:  Ehsan Aali; Habib Ghaznavi; Mohammad Soleiman Soltanpour; Massoud Mahmoudian; Massoumeh Shafiei
Journal:  Iran J Med Sci       Date:  2021-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.